psychological reasons, page-12

re: gsk admits to production increase! Relenza, the only other drug recommended for bird flu, is also in short supply, said Patty Seif, a spokeswoman for its manufacturer, GlaxoSmithKline.

Global sales of Relenza were $5.5 million last year. That figure is expected to rise sharply as the company fills bulk orders from governments that will exhaust most production capacity.

"We are doing everything we can to ramp up production," Seif said. "But if demand becomes excessive we won't be able to meet it."

http://www.latimes.com/business/la-fi-tamiflu13oct13,1,2340919.story?coll=la-headlines-business&ctrack=1&cset=true